Replies to post #18116 on RespireRx Pharmaceuticals Inc (RSPI)

[RBlatch]

Well, the excellent news to be taken from this today is that there are NO safety issues!.

That's great news even though it was expected. One hurdle behind us.

Now we just need evidence that it works.

Cordially,
RBlatch

[Aiming4]

Gfp - you're usually pretty good about commenting on trial design concerns... was this a miss by Cortex in not including more patients from the start?

Given the binarily (probably not a world) critical need to get good trial results in a timely manner from these 2 trials, it's disconcerting to see them delayed 2 and 4 weeks respectively.

And what do you make of RD-01 data now not being released earlier than the RD-02 data?

[ombowstring]

Hi gang,

Although safety issues were the primary subject of today's press release, I presume that efficacy results will be reported towards the end of July. Correct?